The nation of Zimbabwe has turned down a substantial US healthcare agreement valued at $367m (£272m) spanning five years due to the United States' insistence on confidential data.
This rejection became public following a internal memorandum dated December was leaked, revealing that President Emmerson Mnangagwa believed the deal was "lopsided".
A government spokesperson later clarified that the United States was seeking biological samples for scientific study and profit but was not willing to guarantee the resulting advantages from any future treatments.
"We will now turn to the difficult and regrettable task of winding down our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had provided more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for more talks to reach a agreement suitable to both sides so the country's critical HIV programme can continue.
Broader Context
This rejection follows a similar situation in neighbouring Kenya, where a high court halted a related deal with the US after legal challenges were raised about the safety of Kenyans' health data.
Since returning to the presidency last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had managed assistance for the US government, but Trump argued its expenditure was "inefficient" and his administration was seeking government-to-government deals to enhance transparency and accountability.
As per reports, 16 African countries have to date signed similar agreements, representing more than $18.3bn in new funding.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration would have delivered immense benefits for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy through American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana maintained the arrangement was "unfair".
"Zimbabwe was being asked to surrender its genetic material and health information for a long time, with no corresponding guarantee of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"Put simply, our country would provide the basic resources for medical research without any certainty that the end products would be accessible to our citizens if a future pandemic emerge."
Sovereignty and International Frameworks
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were undermining structures previously established via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing system designed to manage potential global health emergencies.
"This system is designed to guarantee that when a country provides its samples, the benefits – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome further dialogue with our American counterparts on how future co-operation might be arranged in a manner that honours the independence and dignity of both nations."
Medical Community Response
Medical experts said it understood the government's concerns, but suggested that negotiations need to persist since much of the country's HIV programmes were funded by external financing.
"In cases where specific concerns exist, such as those involving data governance or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," the group said.
The situation emphasises the ongoing debate between accepting much-needed foreign assistance and safeguarding a country's data in an ever more data-driven world.